Wealthy & Wise| Know when to fold them
Wealthy & Wise| Know when to fold them
About this video
This week on Wealthy & Wise, we tackle one of the toughest calls any investor faces: should you let your winners run, or trim them and rebalance?
Every portfolio drifts over time. Your winners quietly grow into a larger and larger slice, while the laggards shrink away. At some point almost every investor has to ask whether it's time to take some profit off the table, or whether selling what has gone up is exactly the wrong move.
The answer isn't as simple as trimming whatever has risen. It comes down to how well you actually understand the businesses you own. Rebalancing can impose valuable discipline and strip the emotion out of a decision, but for an investor who knows their companies deeply, selling a great business just because it has grown can be a costly mistake. And timing the market? Those who pick the top or the bottom are usually either very lucky or lying.
Teaminvest's Howard Coleman and Focus Partners' David Lane unpack when rebalancing makes sense, when it can quietly hurt long term returns, and why a portfolio review doesn't have to mean making a single change. Then they put the theory to work on two scenarios every investor eventually meets: the winner that has grown too big, and the blue chip that's just been sold off. Plus a viewer question on buying into reporting season.
The stocks in the frame: CSL (ASX:CSL), Pro Medicus (ASX:PME), TechnologyOne (ASX:TNE) and XRF Scientific (ASX:XRF).